nodes	percent_of_prediction	percent_of_DWPC	metapath
Saxagliptin—SLCO4C1—Methotrexate—urinary bladder cancer	0.22	0.315	CbGbCtD
Saxagliptin—ABCC1—Epirubicin—urinary bladder cancer	0.116	0.166	CbGbCtD
Saxagliptin—ABCC1—Etoposide—urinary bladder cancer	0.0904	0.129	CbGbCtD
Saxagliptin—ABCC1—Doxorubicin—urinary bladder cancer	0.0617	0.0883	CbGbCtD
Saxagliptin—ABCC1—Methotrexate—urinary bladder cancer	0.0597	0.0855	CbGbCtD
Saxagliptin—CYP3A4—Thiotepa—urinary bladder cancer	0.0482	0.069	CbGbCtD
Saxagliptin—SLC22A8—Methotrexate—urinary bladder cancer	0.0464	0.0665	CbGbCtD
Saxagliptin—CYP3A5—Etoposide—urinary bladder cancer	0.0335	0.048	CbGbCtD
Saxagliptin—CYP3A4—Etoposide—urinary bladder cancer	0.0131	0.0187	CbGbCtD
Saxagliptin—DPP9—prostate gland—urinary bladder cancer	0.0111	0.0917	CbGeAlD
Saxagliptin—DPP8—prostate gland—urinary bladder cancer	0.0101	0.0835	CbGeAlD
Saxagliptin—CYP3A4—Doxorubicin—urinary bladder cancer	0.00892	0.0128	CbGbCtD
Saxagliptin—DPP8—seminal vesicle—urinary bladder cancer	0.00853	0.0706	CbGeAlD
Saxagliptin—SLC22A8—urine—urinary bladder cancer	0.00776	0.0643	CbGeAlD
Saxagliptin—DPP8—smooth muscle tissue—urinary bladder cancer	0.00714	0.0591	CbGeAlD
Saxagliptin—DPP8—urethra—urinary bladder cancer	0.00675	0.0559	CbGeAlD
Saxagliptin—SLCO4C1—seminal vesicle—urinary bladder cancer	0.00539	0.0447	CbGeAlD
Saxagliptin—DPP8—vagina—urinary bladder cancer	0.00498	0.0412	CbGeAlD
Saxagliptin—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—CDX2—urinary bladder cancer	0.00491	0.118	CbGpPWpGaD
Saxagliptin—DPP4—Incretin synthesis, secretion, and inactivation—CDX2—urinary bladder cancer	0.00437	0.105	CbGpPWpGaD
Saxagliptin—SLCO4C1—renal system—urinary bladder cancer	0.00435	0.036	CbGeAlD
Saxagliptin—DPP4—prostate gland—urinary bladder cancer	0.00423	0.0351	CbGeAlD
Saxagliptin—CYP3A4—urine—urinary bladder cancer	0.00385	0.0319	CbGeAlD
Saxagliptin—DPP4—seminal vesicle—urinary bladder cancer	0.00358	0.0297	CbGeAlD
Saxagliptin—DPP9—lymph node—urinary bladder cancer	0.00354	0.0293	CbGeAlD
Saxagliptin—DPP8—lymph node—urinary bladder cancer	0.00322	0.0267	CbGeAlD
Saxagliptin—SLCO4C1—vagina—urinary bladder cancer	0.00315	0.0261	CbGeAlD
Saxagliptin—DPP4—epithelium—urinary bladder cancer	0.00311	0.0258	CbGeAlD
Saxagliptin—DPP4—smooth muscle tissue—urinary bladder cancer	0.003	0.0248	CbGeAlD
Saxagliptin—DPP4—renal system—urinary bladder cancer	0.00289	0.0239	CbGeAlD
Saxagliptin—SLC22A8—prostate gland—urinary bladder cancer	0.00279	0.0231	CbGeAlD
Saxagliptin—ABCC1—prostate gland—urinary bladder cancer	0.00239	0.0198	CbGeAlD
Saxagliptin—DPP4—female reproductive system—urinary bladder cancer	0.00231	0.0191	CbGeAlD
Saxagliptin—DPP4—vagina—urinary bladder cancer	0.00209	0.0173	CbGeAlD
Saxagliptin—ABCC1—seminal vesicle—urinary bladder cancer	0.00202	0.0168	CbGeAlD
Saxagliptin—SLC22A8—renal system—urinary bladder cancer	0.0019	0.0157	CbGeAlD
Saxagliptin—ABCC1—Synthesis of Leukotrienes (LT) and Eoxins (EX)—CYP4B1—urinary bladder cancer	0.00188	0.0451	CbGpPWpGaD
Saxagliptin—CYP3A5—prostate gland—urinary bladder cancer	0.00184	0.0152	CbGeAlD
Saxagliptin—ABCC1—Cobalamin (Cbl, vitamin B12) transport and metabolism—PRSS3—urinary bladder cancer	0.0018	0.0432	CbGpPWpGaD
Saxagliptin—Myalgia—Valrubicin—urinary bladder cancer	0.00161	0.0116	CcSEcCtD
Saxagliptin—Opportunistic infection—Methotrexate—urinary bladder cancer	0.00161	0.0115	CcSEcCtD
Saxagliptin—ABCC1—urethra—urinary bladder cancer	0.0016	0.0133	CbGeAlD
Saxagliptin—Opportunistic infection—Epirubicin—urinary bladder cancer	0.0015	0.0108	CcSEcCtD
Saxagliptin—DPP4—Peptide hormone metabolism—CDX2—urinary bladder cancer	0.00148	0.0355	CbGpPWpGaD
Saxagliptin—Infection—Carboplatin—urinary bladder cancer	0.00142	0.0102	CcSEcCtD
Saxagliptin—Musculoskeletal discomfort—Valrubicin—urinary bladder cancer	0.00141	0.0101	CcSEcCtD
Saxagliptin—Opportunistic infection—Doxorubicin—urinary bladder cancer	0.00139	0.00999	CcSEcCtD
Saxagliptin—DPP4—lymph node—urinary bladder cancer	0.00135	0.0112	CbGeAlD
Saxagliptin—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00133	0.0318	CbGpPWpGaD
Saxagliptin—CYP3A5—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00132	0.0316	CbGpPWpGaD
Saxagliptin—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.00127	0.0091	CcSEcCtD
Saxagliptin—CYP3A5—renal system—urinary bladder cancer	0.00125	0.0104	CbGeAlD
Saxagliptin—Abdominal pain—Valrubicin—urinary bladder cancer	0.00122	0.0088	CcSEcCtD
Saxagliptin—Lymphopenia—Epirubicin—urinary bladder cancer	0.00118	0.0085	CcSEcCtD
Saxagliptin—ABCC1—vagina—urinary bladder cancer	0.00118	0.00979	CbGeAlD
Saxagliptin—Multiple fractures—Methotrexate—urinary bladder cancer	0.00111	0.008	CcSEcCtD
Saxagliptin—Fracture—Methotrexate—urinary bladder cancer	0.00111	0.008	CcSEcCtD
Saxagliptin—Asthenia—Valrubicin—urinary bladder cancer	0.00111	0.00798	CcSEcCtD
Saxagliptin—Pruritus—Valrubicin—urinary bladder cancer	0.0011	0.00787	CcSEcCtD
Saxagliptin—Lymphopenia—Doxorubicin—urinary bladder cancer	0.00109	0.00787	CcSEcCtD
Saxagliptin—CYP3A5—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00107	0.0256	CbGpPWpGaD
Saxagliptin—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.00104	0.00751	CcSEcCtD
Saxagliptin—Dizziness—Valrubicin—urinary bladder cancer	0.00102	0.00736	CcSEcCtD
Saxagliptin—Blood creatinine increased—Thiotepa—urinary bladder cancer	0.00102	0.00735	CcSEcCtD
Saxagliptin—Vomiting—Valrubicin—urinary bladder cancer	0.000984	0.00707	CcSEcCtD
Saxagliptin—Rash—Valrubicin—urinary bladder cancer	0.000976	0.00702	CcSEcCtD
Saxagliptin—Dermatitis—Valrubicin—urinary bladder cancer	0.000975	0.00701	CcSEcCtD
Saxagliptin—Headache—Valrubicin—urinary bladder cancer	0.00097	0.00697	CcSEcCtD
Saxagliptin—ABCC1—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000942	0.0225	CbGpPWpGaD
Saxagliptin—CYP3A4—renal system—urinary bladder cancer	0.000941	0.0078	CbGeAlD
Saxagliptin—Nausea—Valrubicin—urinary bladder cancer	0.00092	0.00661	CcSEcCtD
Saxagliptin—Fatigue—Mitomycin—urinary bladder cancer	0.00092	0.00661	CcSEcCtD
Saxagliptin—SLCO4C1—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000911	0.0218	CbGpPWpGaD
Saxagliptin—CYP3A5—vagina—urinary bladder cancer	0.000908	0.00752	CbGeAlD
Saxagliptin—Face oedema—Gemcitabine—urinary bladder cancer	0.000886	0.00637	CcSEcCtD
Saxagliptin—Blood creatinine increased—Gemcitabine—urinary bladder cancer	0.00086	0.00618	CcSEcCtD
Saxagliptin—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.000842	0.0202	CbGpPWpGaD
Saxagliptin—Infestation NOS—Thiotepa—urinary bladder cancer	0.000841	0.00604	CcSEcCtD
Saxagliptin—Infestation—Thiotepa—urinary bladder cancer	0.000841	0.00604	CcSEcCtD
Saxagliptin—Face oedema—Cisplatin—urinary bladder cancer	0.000826	0.00594	CcSEcCtD
Saxagliptin—Nasopharyngitis—Fluorouracil—urinary bladder cancer	0.000807	0.0058	CcSEcCtD
Saxagliptin—Blood creatinine increased—Cisplatin—urinary bladder cancer	0.000802	0.00576	CcSEcCtD
Saxagliptin—Asthenia—Mitomycin—urinary bladder cancer	0.000765	0.0055	CcSEcCtD
Saxagliptin—Nasopharyngitis—Cisplatin—urinary bladder cancer	0.000765	0.0055	CcSEcCtD
Saxagliptin—ABCC1—lymph node—urinary bladder cancer	0.000764	0.00633	CbGeAlD
Saxagliptin—CYP3A4—female reproductive system—urinary bladder cancer	0.000754	0.00624	CbGeAlD
Saxagliptin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—GSTO2—urinary bladder cancer	0.000734	0.0176	CbGpPWpGaD
Saxagliptin—Pancreatitis—Cisplatin—urinary bladder cancer	0.000725	0.00521	CcSEcCtD
Saxagliptin—Upper respiratory tract infection—Fluorouracil—urinary bladder cancer	0.000725	0.00521	CcSEcCtD
Saxagliptin—Dizziness—Mitomycin—urinary bladder cancer	0.000705	0.00507	CcSEcCtD
Saxagliptin—Infestation—Fluorouracil—urinary bladder cancer	0.000696	0.005	CcSEcCtD
Saxagliptin—Infestation NOS—Fluorouracil—urinary bladder cancer	0.000696	0.005	CcSEcCtD
Saxagliptin—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.000694	0.0166	CbGpPWpGaD
Saxagliptin—Immune system disorder—Thiotepa—urinary bladder cancer	0.000682	0.0049	CcSEcCtD
Saxagliptin—Vomiting—Mitomycin—urinary bladder cancer	0.000678	0.00487	CcSEcCtD
Saxagliptin—Urinary tract infection—Fluorouracil—urinary bladder cancer	0.000676	0.00486	CcSEcCtD
Saxagliptin—Rash—Mitomycin—urinary bladder cancer	0.000672	0.00483	CcSEcCtD
Saxagliptin—Dermatitis—Mitomycin—urinary bladder cancer	0.000672	0.00483	CcSEcCtD
Saxagliptin—Headache—Mitomycin—urinary bladder cancer	0.000668	0.0048	CcSEcCtD
Saxagliptin—Malnutrition—Thiotepa—urinary bladder cancer	0.000657	0.00472	CcSEcCtD
Saxagliptin—Sinusitis—Fluorouracil—urinary bladder cancer	0.000653	0.00469	CcSEcCtD
Saxagliptin—Nausea—Mitomycin—urinary bladder cancer	0.000634	0.00455	CcSEcCtD
Saxagliptin—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.000626	0.0045	CcSEcCtD
Saxagliptin—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.000614	0.0147	CbGpPWpGaD
Saxagliptin—Infestation NOS—Etoposide—urinary bladder cancer	0.000604	0.00434	CcSEcCtD
Saxagliptin—Infestation—Etoposide—urinary bladder cancer	0.000604	0.00434	CcSEcCtD
Saxagliptin—Immune system disorder—Gemcitabine—urinary bladder cancer	0.000574	0.00412	CcSEcCtD
Saxagliptin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—SLC19A1—urinary bladder cancer	0.000571	0.0137	CbGpPWpGaD
Saxagliptin—Myalgia—Thiotepa—urinary bladder cancer	0.000559	0.00402	CcSEcCtD
Saxagliptin—Arthralgia—Thiotepa—urinary bladder cancer	0.000559	0.00402	CcSEcCtD
Saxagliptin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PRSS3—urinary bladder cancer	0.000556	0.0133	CbGpPWpGaD
Saxagliptin—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000556	0.00399	CcSEcCtD
Saxagliptin—Immune system disorder—Cisplatin—urinary bladder cancer	0.000535	0.00384	CcSEcCtD
Saxagliptin—Infection—Thiotepa—urinary bladder cancer	0.000533	0.00383	CcSEcCtD
Saxagliptin—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000525	0.00377	CcSEcCtD
Saxagliptin—Skin disorder—Thiotepa—urinary bladder cancer	0.000521	0.00374	CcSEcCtD
Saxagliptin—Malnutrition—Cisplatin—urinary bladder cancer	0.000515	0.0037	CcSEcCtD
Saxagliptin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000513	0.0123	CbGpPWpGaD
Saxagliptin—Flatulence—Cisplatin—urinary bladder cancer	0.000508	0.00365	CcSEcCtD
Saxagliptin—CYP3A5—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000506	0.0121	CbGpPWpGaD
Saxagliptin—ABCC1—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000501	0.012	CbGpPWpGaD
Saxagliptin—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000498	0.0119	CbGpPWpGaD
Saxagliptin—Immune system disorder—Etoposide—urinary bladder cancer	0.00049	0.00352	CcSEcCtD
Saxagliptin—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000489	0.00351	CcSEcCtD
Saxagliptin—Dyspepsia—Thiotepa—urinary bladder cancer	0.000472	0.00339	CcSEcCtD
Saxagliptin—Myalgia—Gemcitabine—urinary bladder cancer	0.000471	0.00338	CcSEcCtD
Saxagliptin—Arthralgia—Gemcitabine—urinary bladder cancer	0.000471	0.00338	CcSEcCtD
Saxagliptin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000467	0.00336	CcSEcCtD
Saxagliptin—SLCO4C1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000463	0.0111	CbGpPWpGaD
Saxagliptin—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000463	0.00333	CcSEcCtD
Saxagliptin—Myalgia—Fluorouracil—urinary bladder cancer	0.000463	0.00333	CcSEcCtD
Saxagliptin—Fatigue—Thiotepa—urinary bladder cancer	0.000462	0.00332	CcSEcCtD
Saxagliptin—Purpura—Epirubicin—urinary bladder cancer	0.000456	0.00328	CcSEcCtD
Saxagliptin—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000451	0.00324	CcSEcCtD
Saxagliptin—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.00045	0.00324	CcSEcCtD
Saxagliptin—Infection—Gemcitabine—urinary bladder cancer	0.000448	0.00322	CcSEcCtD
Saxagliptin—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000444	0.00319	CcSEcCtD
Saxagliptin—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000442	0.00318	CcSEcCtD
Saxagliptin—Infection—Fluorouracil—urinary bladder cancer	0.000441	0.00317	CcSEcCtD
Saxagliptin—Myalgia—Cisplatin—urinary bladder cancer	0.000439	0.00315	CcSEcCtD
Saxagliptin—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000439	0.00315	CcSEcCtD
Saxagliptin—Skin disorder—Gemcitabine—urinary bladder cancer	0.000438	0.00315	CcSEcCtD
Saxagliptin—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000437	0.0105	CbGpPWpGaD
Saxagliptin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000436	0.00313	CcSEcCtD
Saxagliptin—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000434	0.00312	CcSEcCtD
Saxagliptin—Urticaria—Thiotepa—urinary bladder cancer	0.000426	0.00306	CcSEcCtD
Saxagliptin—Face oedema—Epirubicin—urinary bladder cancer	0.000424	0.00305	CcSEcCtD
Saxagliptin—Abdominal pain—Thiotepa—urinary bladder cancer	0.000424	0.00305	CcSEcCtD
Saxagliptin—Purpura—Doxorubicin—urinary bladder cancer	0.000422	0.00303	CcSEcCtD
Saxagliptin—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000421	0.00302	CcSEcCtD
Saxagliptin—ABCC1—S1P1 pathway—RHOA—urinary bladder cancer	0.000418	0.01	CbGpPWpGaD
Saxagliptin—Infection—Cisplatin—urinary bladder cancer	0.000418	0.003	CcSEcCtD
Saxagliptin—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.000417	0.00299	CcSEcCtD
Saxagliptin—CYP3A5—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000416	0.00996	CbGpPWpGaD
Saxagliptin—CYP3A5—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000414	0.00992	CbGpPWpGaD
Saxagliptin—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000412	0.00296	CcSEcCtD
Saxagliptin—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000412	0.00296	CcSEcCtD
Saxagliptin—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000411	0.00295	CcSEcCtD
Saxagliptin—Skin disorder—Cisplatin—urinary bladder cancer	0.000408	0.00294	CcSEcCtD
Saxagliptin—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000404	0.0029	CcSEcCtD
Saxagliptin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000399	0.00287	CcSEcCtD
Saxagliptin—Pancreatitis—Methotrexate—urinary bladder cancer	0.000398	0.00286	CcSEcCtD
Saxagliptin—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000395	0.00284	CcSEcCtD
Saxagliptin—DPP4—Peptide hormone metabolism—IGF1—urinary bladder cancer	0.000393	0.00941	CbGpPWpGaD
Saxagliptin—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000393	0.00282	CcSEcCtD
Saxagliptin—Face oedema—Doxorubicin—urinary bladder cancer	0.000393	0.00282	CcSEcCtD
Saxagliptin—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00039	0.00281	CcSEcCtD
Saxagliptin—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00039	0.0028	CcSEcCtD
Saxagliptin—Fatigue—Gemcitabine—urinary bladder cancer	0.000389	0.0028	CcSEcCtD
Saxagliptin—Gastritis—Epirubicin—urinary bladder cancer	0.000389	0.00279	CcSEcCtD
Saxagliptin—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000385	0.00277	CcSEcCtD
Saxagliptin—Asthenia—Thiotepa—urinary bladder cancer	0.000385	0.00277	CcSEcCtD
Saxagliptin—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000383	0.00275	CcSEcCtD
Saxagliptin—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000383	0.00275	CcSEcCtD
Saxagliptin—Infection—Etoposide—urinary bladder cancer	0.000383	0.00275	CcSEcCtD
Saxagliptin—SLC22A8—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000383	0.00916	CbGpPWpGaD
Saxagliptin—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000381	0.00274	CcSEcCtD
Saxagliptin—Pruritus—Thiotepa—urinary bladder cancer	0.000379	0.00273	CcSEcCtD
Saxagliptin—ABCC1—S1P1 pathway—PTGS2—urinary bladder cancer	0.000378	0.00905	CbGpPWpGaD
Saxagliptin—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000377	0.00271	CcSEcCtD
Saxagliptin—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000377	0.00271	CcSEcCtD
Saxagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000376	0.00899	CbGpPWpGaD
Saxagliptin—Skin disorder—Etoposide—urinary bladder cancer	0.000374	0.00269	CcSEcCtD
Saxagliptin—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000374	0.00269	CcSEcCtD
Saxagliptin—Pancreatitis—Epirubicin—urinary bladder cancer	0.000372	0.00268	CcSEcCtD
Saxagliptin—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000364	0.00261	CcSEcCtD
Saxagliptin—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000363	0.00261	CcSEcCtD
Saxagliptin—Infestation NOS—Methotrexate—urinary bladder cancer	0.000362	0.0026	CcSEcCtD
Saxagliptin—Infestation—Methotrexate—urinary bladder cancer	0.000362	0.0026	CcSEcCtD
Saxagliptin—Gastritis—Doxorubicin—urinary bladder cancer	0.00036	0.00259	CcSEcCtD
Saxagliptin—Dizziness—Thiotepa—urinary bladder cancer	0.000355	0.00255	CcSEcCtD
Saxagliptin—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000353	0.00254	CcSEcCtD
Saxagliptin—Urticaria—Fluorouracil—urinary bladder cancer	0.000352	0.00253	CcSEcCtD
Saxagliptin—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000345	0.00248	CcSEcCtD
Saxagliptin—Vomiting—Thiotepa—urinary bladder cancer	0.000341	0.00245	CcSEcCtD
Saxagliptin—Infestation NOS—Epirubicin—urinary bladder cancer	0.000339	0.00243	CcSEcCtD
Saxagliptin—Infestation—Epirubicin—urinary bladder cancer	0.000339	0.00243	CcSEcCtD
Saxagliptin—Rash—Thiotepa—urinary bladder cancer	0.000338	0.00243	CcSEcCtD
Saxagliptin—Dermatitis—Thiotepa—urinary bladder cancer	0.000338	0.00243	CcSEcCtD
Saxagliptin—Headache—Thiotepa—urinary bladder cancer	0.000336	0.00242	CcSEcCtD
Saxagliptin—SLCO4C1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000335	0.00801	CbGpPWpGaD
Saxagliptin—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000333	0.00239	CcSEcCtD
Saxagliptin—Fatigue—Etoposide—urinary bladder cancer	0.000332	0.00239	CcSEcCtD
Saxagliptin—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000329	0.00237	CcSEcCtD
Saxagliptin—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000327	0.00235	CcSEcCtD
Saxagliptin—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000327	0.00235	CcSEcCtD
Saxagliptin—Asthenia—Gemcitabine—urinary bladder cancer	0.000324	0.00233	CcSEcCtD
Saxagliptin—Pruritus—Gemcitabine—urinary bladder cancer	0.000319	0.00229	CcSEcCtD
Saxagliptin—Nausea—Thiotepa—urinary bladder cancer	0.000319	0.00229	CcSEcCtD
Saxagliptin—Sinusitis—Epirubicin—urinary bladder cancer	0.000318	0.00228	CcSEcCtD
Saxagliptin—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000315	0.00226	CcSEcCtD
Saxagliptin—Pruritus—Fluorouracil—urinary bladder cancer	0.000314	0.00226	CcSEcCtD
Saxagliptin—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000313	0.00225	CcSEcCtD
Saxagliptin—Infestation—Doxorubicin—urinary bladder cancer	0.000313	0.00225	CcSEcCtD
Saxagliptin—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00031	0.00223	CcSEcCtD
Saxagliptin—Urticaria—Etoposide—urinary bladder cancer	0.000306	0.0022	CcSEcCtD
Saxagliptin—Abdominal pain—Etoposide—urinary bladder cancer	0.000305	0.00219	CcSEcCtD
Saxagliptin—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000305	0.00219	CcSEcCtD
Saxagliptin—Asthenia—Cisplatin—urinary bladder cancer	0.000302	0.00217	CcSEcCtD
Saxagliptin—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000299	0.00215	CcSEcCtD
Saxagliptin—ABCC1—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000296	0.00709	CbGpPWpGaD
Saxagliptin—Sinusitis—Doxorubicin—urinary bladder cancer	0.000294	0.00211	CcSEcCtD
Saxagliptin—Immune system disorder—Methotrexate—urinary bladder cancer	0.000293	0.00211	CcSEcCtD
Saxagliptin—Dizziness—Fluorouracil—urinary bladder cancer	0.000293	0.00211	CcSEcCtD
Saxagliptin—Vomiting—Gemcitabine—urinary bladder cancer	0.000287	0.00206	CcSEcCtD
Saxagliptin—Rash—Gemcitabine—urinary bladder cancer	0.000284	0.00204	CcSEcCtD
Saxagliptin—Dermatitis—Gemcitabine—urinary bladder cancer	0.000284	0.00204	CcSEcCtD
Saxagliptin—Hypersensitivity—Etoposide—urinary bladder cancer	0.000284	0.00204	CcSEcCtD
Saxagliptin—CYP3A5—Biological oxidations—GSTZ1—urinary bladder cancer	0.000283	0.00677	CbGpPWpGaD
Saxagliptin—Malnutrition—Methotrexate—urinary bladder cancer	0.000283	0.00203	CcSEcCtD
Saxagliptin—Headache—Gemcitabine—urinary bladder cancer	0.000283	0.00203	CcSEcCtD
Saxagliptin—Vomiting—Fluorouracil—urinary bladder cancer	0.000282	0.00203	CcSEcCtD
Saxagliptin—Rash—Fluorouracil—urinary bladder cancer	0.00028	0.00201	CcSEcCtD
Saxagliptin—DPP4—Metabolism of proteins—CDX2—urinary bladder cancer	0.00028	0.00669	CbGpPWpGaD
Saxagliptin—Dermatitis—Fluorouracil—urinary bladder cancer	0.000279	0.00201	CcSEcCtD
Saxagliptin—CYP3A5—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000279	0.00668	CbGpPWpGaD
Saxagliptin—Headache—Fluorouracil—urinary bladder cancer	0.000278	0.002	CcSEcCtD
Saxagliptin—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000277	0.00199	CcSEcCtD
Saxagliptin—Asthenia—Etoposide—urinary bladder cancer	0.000276	0.00199	CcSEcCtD
Saxagliptin—Immune system disorder—Epirubicin—urinary bladder cancer	0.000275	0.00197	CcSEcCtD
Saxagliptin—SLCO4C1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000273	0.00653	CbGpPWpGaD
Saxagliptin—Pruritus—Etoposide—urinary bladder cancer	0.000273	0.00196	CcSEcCtD
Saxagliptin—CYP3A5—Biological oxidations—NAT1—urinary bladder cancer	0.000268	0.00642	CbGpPWpGaD
Saxagliptin—CYP3A5—Biological oxidations—GSTO2—urinary bladder cancer	0.000268	0.00642	CbGpPWpGaD
Saxagliptin—Nausea—Gemcitabine—urinary bladder cancer	0.000268	0.00193	CcSEcCtD
Saxagliptin—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000268	0.00641	CbGpPWpGaD
Saxagliptin—Vomiting—Cisplatin—urinary bladder cancer	0.000267	0.00192	CcSEcCtD
Saxagliptin—Rash—Cisplatin—urinary bladder cancer	0.000265	0.00191	CcSEcCtD
Saxagliptin—Dermatitis—Cisplatin—urinary bladder cancer	0.000265	0.0019	CcSEcCtD
Saxagliptin—CYP3A5—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000265	0.00633	CbGpPWpGaD
Saxagliptin—Malnutrition—Epirubicin—urinary bladder cancer	0.000265	0.0019	CcSEcCtD
Saxagliptin—Nausea—Fluorouracil—urinary bladder cancer	0.000264	0.00189	CcSEcCtD
Saxagliptin—Flatulence—Epirubicin—urinary bladder cancer	0.000261	0.00187	CcSEcCtD
Saxagliptin—Dizziness—Etoposide—urinary bladder cancer	0.000255	0.00183	CcSEcCtD
Saxagliptin—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000254	0.00183	CcSEcCtD
Saxagliptin—Nausea—Cisplatin—urinary bladder cancer	0.00025	0.0018	CcSEcCtD
Saxagliptin—CYP3A5—Biological oxidations—UGT2B7—urinary bladder cancer	0.000245	0.00587	CbGpPWpGaD
Saxagliptin—Vomiting—Etoposide—urinary bladder cancer	0.000245	0.00176	CcSEcCtD
Saxagliptin—Malnutrition—Doxorubicin—urinary bladder cancer	0.000245	0.00176	CcSEcCtD
Saxagliptin—Rash—Etoposide—urinary bladder cancer	0.000243	0.00175	CcSEcCtD
Saxagliptin—Dermatitis—Etoposide—urinary bladder cancer	0.000243	0.00174	CcSEcCtD
Saxagliptin—CYP3A5—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000242	0.00579	CbGpPWpGaD
Saxagliptin—Headache—Etoposide—urinary bladder cancer	0.000241	0.00173	CcSEcCtD
Saxagliptin—Flatulence—Doxorubicin—urinary bladder cancer	0.000241	0.00173	CcSEcCtD
Saxagliptin—Arthralgia—Methotrexate—urinary bladder cancer	0.000241	0.00173	CcSEcCtD
Saxagliptin—Myalgia—Methotrexate—urinary bladder cancer	0.000241	0.00173	CcSEcCtD
Saxagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000239	0.00172	CcSEcCtD
Saxagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000239	0.00571	CbGpPWpGaD
Saxagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000235	0.00563	CbGpPWpGaD
Saxagliptin—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000231	0.00166	CcSEcCtD
Saxagliptin—Infection—Methotrexate—urinary bladder cancer	0.000229	0.00165	CcSEcCtD
Saxagliptin—Nausea—Etoposide—urinary bladder cancer	0.000229	0.00164	CcSEcCtD
Saxagliptin—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000226	0.00162	CcSEcCtD
Saxagliptin—Arthralgia—Epirubicin—urinary bladder cancer	0.000225	0.00162	CcSEcCtD
Saxagliptin—Myalgia—Epirubicin—urinary bladder cancer	0.000225	0.00162	CcSEcCtD
Saxagliptin—Skin disorder—Methotrexate—urinary bladder cancer	0.000224	0.00161	CcSEcCtD
Saxagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000224	0.00161	CcSEcCtD
Saxagliptin—CYP3A5—Biological oxidations—CYP4B1—urinary bladder cancer	0.000221	0.00529	CbGpPWpGaD
Saxagliptin—CYP3A5—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000218	0.00522	CbGpPWpGaD
Saxagliptin—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000216	0.00155	CcSEcCtD
Saxagliptin—Infection—Epirubicin—urinary bladder cancer	0.000215	0.00154	CcSEcCtD
Saxagliptin—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000211	0.00152	CcSEcCtD
Saxagliptin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.00021	0.00151	CcSEcCtD
Saxagliptin—Skin disorder—Epirubicin—urinary bladder cancer	0.00021	0.00151	CcSEcCtD
Saxagliptin—Myalgia—Doxorubicin—urinary bladder cancer	0.000208	0.0015	CcSEcCtD
Saxagliptin—Arthralgia—Doxorubicin—urinary bladder cancer	0.000208	0.0015	CcSEcCtD
Saxagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000207	0.00149	CcSEcCtD
Saxagliptin—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000205	0.00492	CbGpPWpGaD
Saxagliptin—Dyspepsia—Methotrexate—urinary bladder cancer	0.000203	0.00146	CcSEcCtD
Saxagliptin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.0002	0.00144	CcSEcCtD
Saxagliptin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000199	0.00143	CcSEcCtD
Saxagliptin—Fatigue—Methotrexate—urinary bladder cancer	0.000199	0.00143	CcSEcCtD
Saxagliptin—Infection—Doxorubicin—urinary bladder cancer	0.000199	0.00143	CcSEcCtD
Saxagliptin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000197	0.00141	CcSEcCtD
Saxagliptin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000196	0.00141	CcSEcCtD
Saxagliptin—SLC22A8—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000194	0.00465	CbGpPWpGaD
Saxagliptin—Skin disorder—Doxorubicin—urinary bladder cancer	0.000194	0.0014	CcSEcCtD
Saxagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000193	0.00463	CbGpPWpGaD
Saxagliptin—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000193	0.00461	CbGpPWpGaD
Saxagliptin—Dyspepsia—Epirubicin—urinary bladder cancer	0.00019	0.00137	CcSEcCtD
Saxagliptin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000189	0.00136	CcSEcCtD
Saxagliptin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000186	0.00134	CcSEcCtD
Saxagliptin—Fatigue—Epirubicin—urinary bladder cancer	0.000186	0.00134	CcSEcCtD
Saxagliptin—SLCO4C1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000184	0.00441	CbGpPWpGaD
Saxagliptin—Urticaria—Methotrexate—urinary bladder cancer	0.000183	0.00132	CcSEcCtD
Saxagliptin—Abdominal pain—Methotrexate—urinary bladder cancer	0.000182	0.00131	CcSEcCtD
Saxagliptin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000182	0.00131	CcSEcCtD
Saxagliptin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000177	0.00127	CcSEcCtD
Saxagliptin—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000176	0.00126	CcSEcCtD
Saxagliptin—DPP4—Metabolism of proteins—IGFBP3—urinary bladder cancer	0.000176	0.0042	CbGpPWpGaD
Saxagliptin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000176	0.0042	CbGpPWpGaD
Saxagliptin—ABCC1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000174	0.00418	CbGpPWpGaD
Saxagliptin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000173	0.00124	CcSEcCtD
Saxagliptin—Fatigue—Doxorubicin—urinary bladder cancer	0.000172	0.00124	CcSEcCtD
Saxagliptin—Urticaria—Epirubicin—urinary bladder cancer	0.000172	0.00123	CcSEcCtD
Saxagliptin—Abdominal pain—Epirubicin—urinary bladder cancer	0.000171	0.00123	CcSEcCtD
Saxagliptin—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00017	0.00122	CcSEcCtD
Saxagliptin—Asthenia—Methotrexate—urinary bladder cancer	0.000166	0.00119	CcSEcCtD
Saxagliptin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000163	0.00117	CcSEcCtD
Saxagliptin—Pruritus—Methotrexate—urinary bladder cancer	0.000163	0.00117	CcSEcCtD
Saxagliptin—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000159	0.00114	CcSEcCtD
Saxagliptin—Urticaria—Doxorubicin—urinary bladder cancer	0.000159	0.00114	CcSEcCtD
Saxagliptin—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000158	0.00114	CcSEcCtD
Saxagliptin—ABCC1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000155	0.00372	CbGpPWpGaD
Saxagliptin—Asthenia—Epirubicin—urinary bladder cancer	0.000155	0.00111	CcSEcCtD
Saxagliptin—Pruritus—Epirubicin—urinary bladder cancer	0.000153	0.0011	CcSEcCtD
Saxagliptin—Dizziness—Methotrexate—urinary bladder cancer	0.000153	0.0011	CcSEcCtD
Saxagliptin—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000147	0.00106	CcSEcCtD
Saxagliptin—CYP3A5—Biological oxidations—NAT2—urinary bladder cancer	0.000147	0.00352	CbGpPWpGaD
Saxagliptin—Vomiting—Methotrexate—urinary bladder cancer	0.000147	0.00105	CcSEcCtD
Saxagliptin—Rash—Methotrexate—urinary bladder cancer	0.000146	0.00105	CcSEcCtD
Saxagliptin—Dermatitis—Methotrexate—urinary bladder cancer	0.000145	0.00104	CcSEcCtD
Saxagliptin—CYP3A5—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000145	0.00347	CbGpPWpGaD
Saxagliptin—Headache—Methotrexate—urinary bladder cancer	0.000145	0.00104	CcSEcCtD
Saxagliptin—Asthenia—Doxorubicin—urinary bladder cancer	0.000143	0.00103	CcSEcCtD
Saxagliptin—Dizziness—Epirubicin—urinary bladder cancer	0.000143	0.00103	CcSEcCtD
Saxagliptin—Pruritus—Doxorubicin—urinary bladder cancer	0.000141	0.00102	CcSEcCtD
Saxagliptin—SLC22A8—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000141	0.00337	CbGpPWpGaD
Saxagliptin—Vomiting—Epirubicin—urinary bladder cancer	0.000137	0.000987	CcSEcCtD
Saxagliptin—Nausea—Methotrexate—urinary bladder cancer	0.000137	0.000985	CcSEcCtD
Saxagliptin—Rash—Epirubicin—urinary bladder cancer	0.000136	0.000979	CcSEcCtD
Saxagliptin—Dermatitis—Epirubicin—urinary bladder cancer	0.000136	0.000978	CcSEcCtD
Saxagliptin—Headache—Epirubicin—urinary bladder cancer	0.000135	0.000972	CcSEcCtD
Saxagliptin—ABCC1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000135	0.00322	CbGpPWpGaD
Saxagliptin—Dizziness—Doxorubicin—urinary bladder cancer	0.000132	0.00095	CcSEcCtD
Saxagliptin—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000132	0.00315	CbGpPWpGaD
Saxagliptin—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00013	0.00311	CbGpPWpGaD
Saxagliptin—Nausea—Epirubicin—urinary bladder cancer	0.000128	0.000922	CcSEcCtD
Saxagliptin—Vomiting—Doxorubicin—urinary bladder cancer	0.000127	0.000913	CcSEcCtD
Saxagliptin—Rash—Doxorubicin—urinary bladder cancer	0.000126	0.000906	CcSEcCtD
Saxagliptin—Dermatitis—Doxorubicin—urinary bladder cancer	0.000126	0.000905	CcSEcCtD
Saxagliptin—Headache—Doxorubicin—urinary bladder cancer	0.000125	0.0009	CcSEcCtD
Saxagliptin—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000125	0.00299	CbGpPWpGaD
Saxagliptin—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000125	0.00299	CbGpPWpGaD
Saxagliptin—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000123	0.00294	CbGpPWpGaD
Saxagliptin—Nausea—Doxorubicin—urinary bladder cancer	0.000119	0.000853	CcSEcCtD
Saxagliptin—CYP3A5—Biological oxidations—HPGDS—urinary bladder cancer	0.000118	0.00281	CbGpPWpGaD
Saxagliptin—SLC22A8—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000115	0.00274	CbGpPWpGaD
Saxagliptin—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000114	0.00273	CbGpPWpGaD
Saxagliptin—CYP3A5—Biological oxidations—GSTT1—urinary bladder cancer	0.000114	0.00273	CbGpPWpGaD
Saxagliptin—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000113	0.00269	CbGpPWpGaD
Saxagliptin—ABCC1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000112	0.00269	CbGpPWpGaD
Saxagliptin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—urinary bladder cancer	0.000112	0.00268	CbGpPWpGaD
Saxagliptin—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000103	0.00246	CbGpPWpGaD
Saxagliptin—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000101	0.00242	CbGpPWpGaD
Saxagliptin—ABCC1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	9.16e-05	0.00219	CbGpPWpGaD
Saxagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	8.85e-05	0.00212	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—GSTO2—urinary bladder cancer	8.69e-05	0.00208	CbGpPWpGaD
Saxagliptin—SLCO4C1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.63e-05	0.00207	CbGpPWpGaD
Saxagliptin—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	7.9e-05	0.00189	CbGpPWpGaD
Saxagliptin—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.79e-05	0.00187	CbGpPWpGaD
Saxagliptin—SLC22A8—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	7.74e-05	0.00185	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—GSTZ1—urinary bladder cancer	7.68e-05	0.00184	CbGpPWpGaD
Saxagliptin—DPP4—Metabolism of proteins—IGF1—urinary bladder cancer	7.42e-05	0.00178	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—GSTO2—urinary bladder cancer	7.28e-05	0.00174	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—NAT1—urinary bladder cancer	7.28e-05	0.00174	CbGpPWpGaD
Saxagliptin—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	7.26e-05	0.00174	CbGpPWpGaD
Saxagliptin—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.16e-05	0.00171	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.16e-05	0.00171	CbGpPWpGaD
Saxagliptin—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	6.83e-05	0.00164	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—SLC19A1—urinary bladder cancer	6.76e-05	0.00162	CbGpPWpGaD
Saxagliptin—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	6.74e-05	0.00161	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—UGT2B7—urinary bladder cancer	6.66e-05	0.00159	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—PRSS3—urinary bladder cancer	6.59e-05	0.00158	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—HDAC4—urinary bladder cancer	6.28e-05	0.0015	CbGpPWpGaD
Saxagliptin—ABCC1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.19e-05	0.00148	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—CYP4B1—urinary bladder cancer	5.99e-05	0.00143	CbGpPWpGaD
Saxagliptin—DPP4—Metabolism of proteins—CXCL8—urinary bladder cancer	5.97e-05	0.00143	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—SLC19A1—urinary bladder cancer	5.66e-05	0.00135	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—PRSS3—urinary bladder cancer	5.52e-05	0.00132	CbGpPWpGaD
Saxagliptin—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	5.46e-05	0.00131	CbGpPWpGaD
Saxagliptin—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	5.3e-05	0.00127	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—LIG1—urinary bladder cancer	4.99e-05	0.00119	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	4.84e-05	0.00116	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	4.59e-05	0.0011	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—NAT1—urinary bladder cancer	4.59e-05	0.0011	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.42e-05	0.00106	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—TYMP—urinary bladder cancer	4.41e-05	0.00106	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.24e-05	0.00101	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	4.2e-05	0.001	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—NAT2—urinary bladder cancer	3.99e-05	0.000954	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—ENO2—urinary bladder cancer	3.81e-05	0.000911	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	3.78e-05	0.000904	CbGpPWpGaD
Saxagliptin—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	3.67e-05	0.000879	CbGpPWpGaD
Saxagliptin—SLC22A8—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.62e-05	0.000867	CbGpPWpGaD
Saxagliptin—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.62e-05	0.000867	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—RBX1—urinary bladder cancer	3.61e-05	0.000864	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	3.57e-05	0.000854	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	3.48e-05	0.000832	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—RRM2—urinary bladder cancer	3.44e-05	0.000824	CbGpPWpGaD
Saxagliptin—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	3.38e-05	0.000808	CbGpPWpGaD
Saxagliptin—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.33e-05	0.000797	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—JAG1—urinary bladder cancer	3.23e-05	0.000773	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—HPGDS—urinary bladder cancer	3.19e-05	0.000763	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—ENO2—urinary bladder cancer	3.19e-05	0.000763	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.17e-05	0.000759	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—GSTT1—urinary bladder cancer	3.09e-05	0.00074	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.04e-05	0.000729	CbGpPWpGaD
Saxagliptin—ABCC1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.89e-05	0.000693	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—TYMP—urinary bladder cancer	2.78e-05	0.000665	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—NQO1—urinary bladder cancer	2.57e-05	0.000615	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—NAT2—urinary bladder cancer	2.51e-05	0.000602	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.49e-05	0.000597	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—NCOR1—urinary bladder cancer	2.35e-05	0.000563	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.25e-05	0.000539	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—ERCC2—urinary bladder cancer	2.21e-05	0.000529	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.17e-05	0.00052	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—RRM2—urinary bladder cancer	2.17e-05	0.000519	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—GSTP1—urinary bladder cancer	2.14e-05	0.000513	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.13e-05	0.000511	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.13e-05	0.000511	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—MTHFR—urinary bladder cancer	2.08e-05	0.000497	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.07e-05	0.000496	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—TERT—urinary bladder cancer	2.07e-05	0.000496	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	2.01e-05	0.000481	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—ENO2—urinary bladder cancer	2.01e-05	0.000481	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—TYMS—urinary bladder cancer	1.99e-05	0.000477	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—NCOR1—urinary bladder cancer	1.97e-05	0.000471	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—GSTM1—urinary bladder cancer	1.97e-05	0.000471	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.95e-05	0.000467	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	1.95e-05	0.000467	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—FGFR3—urinary bladder cancer	1.9e-05	0.000455	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—GPX1—urinary bladder cancer	1.89e-05	0.000451	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—ERCC2—urinary bladder cancer	1.85e-05	0.000443	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.76e-05	0.00042	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—MTHFR—urinary bladder cancer	1.74e-05	0.000417	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.66e-05	0.000397	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—NQO1—urinary bladder cancer	1.62e-05	0.000388	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—CREBBP—urinary bladder cancer	1.62e-05	0.000388	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.62e-05	0.000387	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—RHOA—urinary bladder cancer	1.46e-05	0.000351	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—PPARG—urinary bladder cancer	1.41e-05	0.000338	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—CREBBP—urinary bladder cancer	1.36e-05	0.000325	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—ERBB2—urinary bladder cancer	1.36e-05	0.000325	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.35e-05	0.000323	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—PTGS2—urinary bladder cancer	1.33e-05	0.000317	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.29e-05	0.000309	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.26e-05	0.000301	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.24e-05	0.000297	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.24e-05	0.000297	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.19e-05	0.000285	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.17e-05	0.00028	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.17e-05	0.000279	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—CDKN1A—urinary bladder cancer	1.16e-05	0.000277	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—PTEN—urinary bladder cancer	1.16e-05	0.000277	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—PTGS2—urinary bladder cancer	1.11e-05	0.000266	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—EP300—urinary bladder cancer	1.1e-05	0.000264	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.1e-05	0.000263	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—SRC—urinary bladder cancer	1.07e-05	0.000257	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.01e-05	0.000241	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—PTEN—urinary bladder cancer	9.68e-06	0.000232	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—MYC—urinary bladder cancer	9.61e-06	0.00023	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—EGFR—urinary bladder cancer	9.4e-06	0.000225	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—ENO2—urinary bladder cancer	9.34e-06	0.000224	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	9.34e-06	0.000224	CbGpPWpGaD
Saxagliptin—ABCC1—Metabolism—EP300—urinary bladder cancer	9.23e-06	0.000221	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	9.06e-06	0.000217	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—PPARG—urinary bladder cancer	8.9e-06	0.000213	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—KRAS—urinary bladder cancer	8.88e-06	0.000213	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	8.55e-06	0.000205	CbGpPWpGaD
Saxagliptin—ABCC1—Disease—HRAS—urinary bladder cancer	7.55e-06	0.000181	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—NQO1—urinary bladder cancer	7.53e-06	0.00018	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	7e-06	0.000168	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.28e-06	0.00015	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—PTEN—urinary bladder cancer	6.1e-06	0.000146	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.84e-06	0.00014	CbGpPWpGaD
Saxagliptin—CYP3A5—Metabolism—EP300—urinary bladder cancer	5.82e-06	0.000139	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.77e-06	0.000138	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.77e-06	0.000138	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.53e-06	0.000132	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.43e-06	0.00013	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.1e-06	0.000122	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.14e-06	9.9e-05	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.97e-06	9.51e-05	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.25e-06	7.79e-05	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.84e-06	6.79e-05	CbGpPWpGaD
Saxagliptin—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.71e-06	6.48e-05	CbGpPWpGaD
